FLOW Trial: Semaglutide and 24% Fewer Kidney Events The first dedicated GLP-1 kidney-outcomes trial in type 2 diabetes and CKD. (2026). Diabzen, 4(20), 40-41. https://thediabzen.com/index.php/d/article/view/63